venBio Partners LLC

About The Fund

venBio Partners LLC is a life sciences investment firm specializing in the biotech, medical devices, and broader life sciences sectors. Founded in 2011 and with nearly $1.1 billion in committed capital, venBio focuses on partnering with industry leaders to develop game-changing medicines and technologies. They place a strong emphasis on novel therapeutics aimed at addressing unmet medical needs. The investment expertise of the firm spans across equity and mezzanine financing, catering to various stages of a company's life cycle, including seed, startup, early stage, expansion, later stage, and consolidation, as well as specializing in PIPE and spinout deals. With assets under management totaling around $490 million, venBio is equipped to lead significant funding rounds. Their mission is to support teams in bringing transformative therapies to patients by positioning companies for success from the get-go, ensuring that corporate development is aligned with the requirements of potential acquisition partners. This alignment encompasses a wide array of crucial factors such as intellectual property, chemistry, manufacturing and controls (CMC), clinical trial design, endpoints, powering, and regulatory consideration. The firm's proactive engagement and the experience they bring help companies make a substantial impact in their respective fields, fostering impactful and last-lasting relationships with industry leaders. venBio is also mindful of the strategic considerations of acquisitions early in the investment cycle, positioning its portfolio companies to meet the stringent demands of potential buyers or collaborators. The firm's success is reflected in the FDA approvals of drugs from their investments and the notable capital raises and initial public offerings of their portfolio companies. venBio operates from its headquarters located at 360 University Avenue, Palo Alto, California, and has additional offices in San Francisco and Seattle.